ASEP Medical Holdings Inc., together with its subsidiaries, engages in the acquisition of research and development assets, technologies, and businesses in the area of life sciences and medical diagnostics. It offers peptide technologies that cover therapeutic applications, including bacterial biofilm infections, anti-inflammatory, antibiotic synergy, and immune modulating; diagnostic kits for predicting the onset of severe sepsis; and medical devices with anti-microbial and antifouling coating. The company was formerly known as Trenchant Life Sciences Investment Corp. and changed its name to ASEP Medical Holdings Inc. in November 2021. ASEP Medical Holdings Inc. was incorporated in 2021 and is headquartered in Victoria, Canada.…
ASEP Medical Holdings (CNSX: ASEP) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3 employees.
The shares were at 0.1000 CAD on 19 November 2026, down 80.0% over 52 weeks. Its 52-week range is 0.0550 CAD to 0.5000 CAD: the price is 80.0% below the high and 81.8% above the low.
Its market capitalisation is 1.11M CAD.
ASEP Medical Holdings reports return on equity of -211.2% and flat revenue year over year.
Its debt exceeds its cash by 420.41K CAD, a debt-to-equity ratio of 0.11. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.
No upcoming events tracked.